Tieteelliset julkaisut

Tulokset kategoriasta tagi hakusanalla LSD. Takaisin

Neural correlates of the LSD experience revealed by multimodal neuroimaging (Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, .., 2016)
Julkaisu:Proceedings of the National Academy of Sciences of the United States of America
Tiivistelmä: LSD:n vaikutuksia aivoissa tutkittiin kolmen aivokuvantamismenetelmän avulla. Kohderyhmänä olivat terveet koehenkilöt. Tutkimuksessa todettiin, että LSD vähentää oletushermoverkostoon luettujen aivoalueiden välistä integraatiota ja toisaalta lisää eri aivoalueiden välistä kytkeytyneisyyttä.

Näköaivokuoren voimistunut verenkierto, näköaivokuoren vaimentuneet alfa-aallot ja primäärisen näköaivokuoren toiminnallisten yhteyksien laajeneminen korreloivat vahvasti koehenkilöiden visuaalisista hallusinaatiosta tekemien arvioiden kanssa.

Lisäksi parahippokampuksen ja retrospleniaalisen aivokuoren välisten yhteyksien vaimeneminen korreloi koehenkilöiden arvioimien egon hälvenemisen ja merkityskokemuksen muuttumisen kanssa.

Myös eri kuvantamismenetelmien välillä havaittiin merkittäviä korrelaatioita.
Menetelmät:Aivokuvantaminen, fMRI, MEG
Tagit: aivot, default mode network, LSD, tietoisuus
URL: http://www.pnas.org/content/113/17/4853.full

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. (Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B,.., 2014)
Julkaisu:The Journal of Nervous and Mental disease
Tiivistelmä: A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases.

Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 μg of LSD (n = 8) or 20 μg of LSD with an open-label crossover to 200 μg of LSD after the initial blinded treatment was unmasked (n = 4).

At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months.

These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.
Aihe:kuolemaan liittyvä ahdistus
Menetelmät:kaksoissokkoutettu, satunnaistettu, lumekontrolloitu, seuranta
Tagit: LSD, pilotti
URL: https://journals.lww.com/jonmd/fulltext/2014/07000/Safety_and_Eff...

Classic hallucinogens in the treatment of addictions. (Bogenschutz MP, Johnson MW, 2016)
Julkaisu:Progress in Neuro-Psychopharmacology & Biological Psychiatry
Tiivistelmä: Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions.

In this paper we provide a comprehensive review of both historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, selectively review other relevant research concerning hallucinogens, and suggest directions for future research. Clinical trial data are very limited except for the use of LSD in the treatment of alcoholism, where a meta-analysis of controlled trials has demonstrated a consistent and clinically significant beneficial effect of high-dose LSD.

Recent pilot studies of psilocybin-assisted treatment of nicotine and alcohol dependence had strikingly positive outcomes, but controlled trials will be necessary to evaluate the efficacy of these treatments. Although plausible biological mechanisms have been proposed, currently the strongest evidence is for the role of mystical or other meaningful experiences as mediators of therapeutic effects.

Classic hallucinogens have an excellent record of safety in the context of clinical research. Given our limited understanding of the clinically relevant effects of classic hallucinogens, there is a wealth of opportunities for research that could contribute important new knowledge and potentially lead to valuable new treatments for addiction.
Tagit: alkoholismi, LSD
URL: https://www.sciencedirect.com/science/article/pii/S02785846150005...

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. (Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Volle.., 2015)
Julkaisu:Biological Psychiatry
Tiivistelmä: BACKGROUND:
After no research in humans for >40 years, there is renewed interest in using lysergic acid diethylamide (LSD) in clinical psychiatric research and practice. There are no modern studies on the subjective and autonomic effects of LSD, and its endocrine effects are unknown. In animals, LSD disrupts prepulse inhibition (PPI) of the acoustic startle response, and patients with schizophrenia exhibit similar impairments in PPI. However, no data are available on the effects of LSD on PPI in humans.

In a double-blind, randomized, placebo-controlled, crossover study, LSD (200 μg) and placebo were administered to 16 healthy subjects (8 women, 8 men). Outcome measures included psychometric scales; investigator ratings; PPI of the acoustic startle response; and autonomic, endocrine, and adverse effects.

Administration of LSD to healthy subjects produced pronounced alterations in waking consciousness that lasted 12 hours. The predominant effects induced by LSD included visual hallucinations, audiovisual synesthesia, and positively experienced derealization and depersonalization phenomena. Subjective well-being, happiness, closeness to others, openness, and trust were increased by LSD. Compared with placebo, LSD decreased PPI. LSD significantly increased blood pressure, heart rate, body temperature, pupil size, plasma cortisol, prolactin, oxytocin, and epinephrine. Adverse effects produced by LSD completely subsided within 72 hours. No severe acute adverse effects were observed.

In addition to marked hallucinogenic effects, LSD exerts methylenedioxymethamphetamine-like empathogenic mood effects that may be useful in psychotherapy. LSD altered sensorimotor gating in a human model of psychosis, supporting the use of LSD in translational psychiatric research. In a controlled clinical setting, LSD can be used safely, but it produces significant sympathomimetic stimulation.
Aihe:haitta-arvio, yleiset vaikutukset
Menetelmät:kaksoissokkoutettu, satunnaistettu, lumekontrolloitu, vaihtovuoroinen
Tagit: LSD
URL: https://www.biologicalpsychiatryjournal.com/article/S0006-3223(14...